CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1629985
Long-Term Survival After Targeted Therapy Plus Immunotherapy Without Chemotherapy in Advanced Gallbladder Carcinoma: A Case Report and Literature Review
Provisionally accepted
- 1Shulan Hangzhou Hospital, Hangzhou, China
- 2Women & Children Health Care Hospital of Quzhou, quzhou, China
- 3Hangzhou Seventh People's Hospital, hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Gallbladder carcinoma (GBC) is a highly aggressive malignancy with limited treatment options and poor prognosis, particularly in advanced stages. Traditional chemotherapy often yields modest outcomes and can be poorly tolerated. Materials and Methods We report a case of a 59-year-old woman with stage IVA GBC who was unable to tolerate first-line gemcitabine and cisplatin due to severe adverse effects. Next-generation sequencing revealed a moderate tumor mutation burden and microsatellite-stable status. Based on a multidisciplinary team assessment, she received camrelizumab (PD-1 inhibitor) plus apatinib (VEGFR2 inhibitor). Results: After 11 cycles, imaging demonstrated significant tumor regression and reduced invasion, enabling successful radical resection. Postoperative pathology confirmed moderately differentiated adenocarcinoma with no lymph node involvement. The patient remained disease-free for over two years. Following isolated cervical lymph node metastasis, combination therapy with camrelizumab and surufatinib resulted in complete remission. She continues on maintenance immunotherapy without recurrence five years post-diagnosis. Conclusion: This case highlights the promising potential of targeted therapy and immunotherapy in converting unresectable GBC to operable disease and achieving durable remission, even in patients lacking classic immunotherapy biomarkers. Personalized, non-chemotherapy-based strategies may offer viable alternatives for selected patients.
Keywords: Gallbladder carcinoma, camrelizumab, Apatinib, Immunotherapy, case report
Received: 16 May 2025; Accepted: 05 Sep 2025.
Copyright: © 2025 Chen, Wu, Ding, Gu, Wu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Weilin Wu, Shulan Hangzhou Hospital, Hangzhou, China
Qiyong Li, Shulan Hangzhou Hospital, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.